Furthermore, DZNeP treatment significantly inhibited the tumor growth of the high ANLN m6A-modified HCC PDX models, while these effects were not evident in the two low ANLN m6A-modified HCC PDX lines (Supplementary Fig. 7H). This evidence concerns the gene ANLN and hepatocellular carcinoma.